No Image

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verb Technology Company, Inc.

August 19, 2019 Globe Newswire 0

LOS ANGELES, Aug. 19, 2019 (GLOBE NEWSWIRE) — Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming September 9, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of Verb Technology Company, Inc. …

The post Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Verb Technology Company, Inc. appeared first on Wolfe’s Blog.

No Image

Vera Bradley Co-Founder Patricia R. Miller Announces Retirement From the Company’s Board of Directors

August 19, 2019 Globe Newswire 0

FORT WAYNE, Ind., Aug. 19, 2019 (GLOBE NEWSWIRE) — Vera Bradley (NASDAQ:VRA) (the “Company”) today announced co-founder and long-time board member Patricia R. Miller is retiring from the Company’s board of directors, effective August 30, 2019.

Miller and close friend Barbara Bradley Baekgaard co-founded Vera Bradley in 1982, and Miller has served as a member of the Company’s board of directors since then. From 1982 through June 2010, she served as Co-President of the Company. In June 2010, she was appointed National Spokesperson for the Company where she continued to promote the brand until her retirement in October 2012.

Miller took a leave of absence from the Company in 2005 and 2006 to serve as the first Secretary of Commerce for the State of Indiana and the Chief Executive Officer of the Indiana Economic Development Corporation.  

In 1994, the loss of a dear friend to breast cancer inspired Miller and Baekgaard to add a new dimension to Vera Bradley, establishing the Vera Bradley Foundation for Breast Cancer. To date, the Foundation has raised over $32 million for breast cancer research at the Indiana University Melvin and Bren Simon Cancer Center.

In addition to serving on the board of the Vera Bradley Foundation for Breast Cancer, Miller serves as a director for the Indiana University Foundation, and in the past, she has served as a board member for more than 15 non-profit organizations. Miller has received numerous awards including the Entrepreneur of the Year Award for the State of Indiana from Arthur Young/VENTURE in 1987 (awarded jointly with Baekgaard), the Indiana Commission for Women Torchbearer Award for Business in 2007, the Indiana …

Full story available on Benzinga.com

The post Vera Bradley Co-Founder Patricia R. Miller Announces Retirement From the Company’s Board of Directors appeared first on Wolfe’s Blog.

No Image

FINAL DEADLINE: Rosen, a Globally Recognized Law Firm, Reminds Teva Pharmaceutical Industries Ltd. Investors of Important August 20th Deadline in Securities Class Action – TEVA

August 19, 2019 Globe Newswire 0

NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from August 4, 2017 through May 10, 2019, inclusive (the “Class Period”) of the important August 20, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.

To join the Teva class action, go to http://www.rosenlegal.com/cases-register-1609.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Full story available on Benzinga.com

The post FINAL DEADLINE: Rosen, a Globally Recognized Law Firm, Reminds Teva Pharmaceutical Industries Ltd. Investors of Important August 20th Deadline in Securities Class Action – TEVA appeared first on Wolfe’s Blog.

No Image

FINAL DEADLINE: Rosen, a Globally Recognized Law Firm, Reminds Teva Pharmaceutical Industries Ltd. Investors of Important August 20th Deadline in Securities Class Action – TEVA

August 19, 2019 Globe Newswire 0

NEW YORK, Aug. 19, 2019 (GLOBE NEWSWIRE) — Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) from August 4, 2017 through May 10, 2019, inclusive (the “Class Period”) of the important August 20, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Teva investors under the federal securities laws.

To join the Teva class action, go to http://www.rosenlegal.com/cases-register-1609.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Full story available on Benzinga.com

The post FINAL DEADLINE: Rosen, a Globally Recognized Law Firm, Reminds Teva Pharmaceutical Industries Ltd. Investors of Important August 20th Deadline in Securities Class Action – TEVA appeared first on Wolfe’s Blog.

No Image

7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sunlands Technology Group and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

August 19, 2019 Globe Newswire 0

LOS ANGELES, Aug. 19, 2019 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Sunlands Technology Group (“Sunlands” or “the Company”) (NYSE: STG) for violations of the federal securities laws.

Investors who purchased the Company’s shares pursuant to and/or traceable to the Company’s Initial Public Offering in March 2018 (the “IPO”) are encouraged to contact the firm before August 26, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also …

Full story available on Benzinga.com

The post 7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Sunlands Technology Group and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm appeared first on Wolfe’s Blog.

No Image

7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against EQT Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

August 19, 2019 Globe Newswire 0

LOS ANGELES, Aug. 19, 2019 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against EQT Corporation (“EQT” or “the Company”) (NYSE: EQT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between June 19, 2017 and October 24, 2018, inclusive (the ”Class Period”), are encouraged to contact the firm before August 26, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park …

Full story available on Benzinga.com

The post 7-DAY DEADLINE REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against EQT Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of CannTrust Holdings, Inc. (NYSE:CTST), Realogy Holdings Corporation (NYSE:RLGY), Reckitt Benckiser Group Plc (OTC:RBGLY), and Omnicell, Inc. (NASDAQ:OMCL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

CannTrust Holdings, Inc. (NYSE:CTST)

Lead Plaintiff Deadline: September 9, 2019

Class Period: November 14, 2018 to July 12, 2019

The complaint, filed on July 10, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) that the Company’s Pelham greenhouse did not comply with certain regulations; (3) that, as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) that, as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the CannTrust class action go to: https://bespc.com/ctst

Realogy Holdings Corp. (NYSE:RLGY)

Lead Plaintiff Deadline: …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of CannTrust Holdings, Inc. (NYSE:CTST), Realogy Holdings Corporation (NYSE:RLGY), Reckitt Benckiser Group Plc (OTC:RBGLY), and Omnicell, Inc. (NASDAQ:OMCL). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

CannTrust Holdings, Inc. (NYSE:CTST)

Lead Plaintiff Deadline: September 9, 2019

Class Period: November 14, 2018 to July 12, 2019

The complaint, filed on July 10, 2019, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that the Company was growing cannabis in its Pelham greenhouse while applications for regulatory approval were still pending; (2) that the Company’s Pelham greenhouse did not comply with certain regulations; (3) that, as a result, the Company was reasonably likely to face an inventory hold by Health Canada until the Pelham facility becomes compliant with applicable regulations; (4) that, as a result, the Company’s customers would face shortages and would likely seek product from CannTrust’s competitors; and (5) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

For more information on the CannTrust class action go to: https://bespc.com/ctst

Realogy Holdings Corp. (NYSE:RLGY)

Lead Plaintiff Deadline: …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CannTrust, Realogy, Reckitt Benckiser, and Omnicell and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE:MNK), Oasmia Pharmaceutical AB (NASDAQ:OASM), Aclaris Therapeutics, Inc. (NYSE:ACRS), and Curaleaf Holdings, Inc. (OTC:CURLF).  Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Mallinckrodt Plc (NYSE:MNK)

Lead Plaintiff Deadline: September 24, 2019

Class Period: February 28, 2018 to July 16, 2019

The complaint, filed on July 26, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 16, 2019, post-market, Mallinckrodt announced that the Company was permanently discontinuing the PENNANT Trial assessing Acthar’s safety and efficacy as an ALS treatment. Mallinckrodt stated that it decided “to halt the trial after careful consideration of a recent recommendation by the study’s independent Data and Safety Monitoring Board” (“DSMB”), which “was based on the specific concern for pneumonia, which occurred at a higher rate in the ALS patients receiving Acthar Gel compared to those on placebo” and that “the board also mentioned other adverse events specific to this patient population.” On this news, Mallinckrodt’s stock price fell $0.64 per share, or 7.8%, to close at $7.56 per share on July 17, 2019.

For more information on the Mallinckrodt class …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Mallinckrodt Plc (NYSE:MNK), Oasmia Pharmaceutical AB (NASDAQ:OASM), Aclaris Therapeutics, Inc. (NYSE:ACRS), and Curaleaf Holdings, Inc. (OTC:CURLF).  Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Mallinckrodt Plc (NYSE:MNK)

Lead Plaintiff Deadline: September 24, 2019

Class Period: February 28, 2018 to July 16, 2019

The complaint, filed on July 26, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Acthar posed significant safety concerns that rendered it a non-viable treatment for ALS; (ii) accordingly, Mallinckrodt overstated the viability of Acthar as an ALS treatment; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 16, 2019, post-market, Mallinckrodt announced that the Company was permanently discontinuing the PENNANT Trial assessing Acthar’s safety and efficacy as an ALS treatment. Mallinckrodt stated that it decided “to halt the trial after careful consideration of a recent recommendation by the study’s independent Data and Safety Monitoring Board” (“DSMB”), which “was based on the specific concern for pneumonia, which occurred at a higher rate in the ALS patients receiving Acthar Gel compared to those on placebo” and that “the board also mentioned other adverse events specific to this patient population.” On this news, Mallinckrodt’s stock price fell $0.64 per share, or 7.8%, to close at $7.56 per share on July 17, 2019.

For more information on the Mallinckrodt class …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Mallinckrodt, Oasmia Pharmaceutical, Aclaris Therapeutics, and Curaleaf and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Eagle Bancorp, Inc. (NASDAQ:EGBN), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), L Brands, Inc. (NYSE:LB), and National General Holdings Corp. (NASDAQ:NGHC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Eagle Bancorp, Inc. (NASDAQ:EGBN)

Lead Plaintiff Deadline: September 23, 2019

Class Period: March 2, 2015 to July 19, 2019

The complaint, filed on July 24, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company to undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 17, 2019, Eagle Bancorp disclosed rising legal costs stemming from ongoing internal and government investigations of “the Company’s identification, classification and disclosure of related party transactions; the retirement of certain former officers and directors; and the relationship of the Company and certain of its former officers and directors with a local public official.”

On this news, Eagle Bancorp’s stock price fell $14.30 per share, or 26.75%, to close at $39.15 per share on July 18, 2019.

For more information on the Eagle Bancorp class action go to: https://bespc.com/EGBN

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI)

Lead Plaintiff Deadline: September 23, 2019

Class Period: March 2, 2017 to February 22, 2019

The Complaint, filed on July 23, 2019, alleges that during the Class Period defendants falsely represented the safety and efficacy of selinexor, a pharmaceutical drug intended for the treatment of various types of cancer that Karyopharm was in the process of developing. Specifically, defendants’ material misrepresentations and omissions center on defendants’ claims regarding results from clinical trials for selinexor’s treatment of patients with certain types of blood cancer. During the Class Period, defendants claimed that selinexor studies showed that selinexor was “well-tolerated” by patients and explained that …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Eagle Bancorp, Inc. (NASDAQ:EGBN), Karyopharm Therapeutics, Inc. (NASDAQ:KPTI), L Brands, Inc. (NYSE:LB), and National General Holdings Corp. (NASDAQ:NGHC). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Eagle Bancorp, Inc. (NASDAQ:EGBN)

Lead Plaintiff Deadline: September 23, 2019

Class Period: March 2, 2015 to July 19, 2019

The complaint, filed on July 24, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) Eagle Bancorp’s internal controls and procedures and compliance policies were inadequate; (ii) the foregoing shortcoming created a foreseeable risk of heightened regulatory scrutiny and the need for the Company to undertake its own internal investigations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

On July 17, 2019, Eagle Bancorp disclosed rising legal costs stemming from ongoing internal and government investigations of “the Company’s identification, classification and disclosure of related party transactions; the retirement of certain former officers and directors; and the relationship of the Company and certain of its former officers and directors with a local public official.”

On this news, Eagle Bancorp’s stock price fell $14.30 per share, or 26.75%, to close at $39.15 per share on July 18, 2019.

For more information on the Eagle Bancorp class action go to: https://bespc.com/EGBN

Karyopharm Therapeutics, Inc. (NASDAQ:KPTI)

Lead Plaintiff Deadline: September 23, 2019

Class Period: March 2, 2017 to February 22, 2019

The Complaint, filed on July 23, 2019, alleges that during the Class Period defendants falsely represented the safety and efficacy of selinexor, a pharmaceutical drug intended for the treatment of various types of cancer that Karyopharm was in the process of developing. Specifically, defendants’ material misrepresentations and omissions center on defendants’ claims regarding results from clinical trials for selinexor’s treatment of patients with certain types of blood cancer. During the Class Period, defendants claimed that selinexor studies showed that selinexor was “well-tolerated” by patients and explained that …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Eagle Bancorp, Karyopharm, L Brands, and National General and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diebold Nixdorf, Intelligent Systems, Helius Medical, and Verb Technology and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Diebold Nixdorf, Inc. (NYSE:DBD), Intelligent Systems Corporation (NYSE:INS), Helius Medical Technologies, Inc. (NASDAQ:HSDT), and Verb Technology Company, Inc. (NASDAQ:VERB). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Diebold Nixdorf, Inc. (NYSE:DBD)

Lead Plaintiff Deadline: September 3, 2019

Class Period: February 14, 2017 to July 4, 2017

The complaint, filed on July 2, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was experiencing delays in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle; (ii) the foregoing issues were negatively impacting the Company’s services business and operations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. On July 5, 2017, Diebold disclosed that the Company expected a wider net loss than indicated in its prior guidance for fiscal 2017, from a range of $50 to $75 million to a range of $110 to $125 million net loss.

The Company attributed the lowered expectations to a delay in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle. 6. Following this news, Diebold’s stock price fell $6.40 per share, or nearly 23%, to close at …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diebold Nixdorf, Intelligent Systems, Helius Medical, and Verb Technology and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diebold Nixdorf, Intelligent Systems, Helius Medical, and Verb Technology and Encourages Investors to Contact the Firm

August 18, 2019 Globe Newswire 0

NEW YORK, Aug. 18, 2019 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, P.C. reminds investors that class action lawsuits have been commenced on behalf of stockholders of Diebold Nixdorf, Inc. (NYSE:DBD), Intelligent Systems Corporation (NYSE:INS), Helius Medical Technologies, Inc. (NASDAQ:HSDT), and Verb Technology Company, Inc. (NASDAQ:VERB). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link provided.

Diebold Nixdorf, Inc. (NYSE:DBD)

Lead Plaintiff Deadline: September 3, 2019

Class Period: February 14, 2017 to July 4, 2017

The complaint, filed on July 2, 2019, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business, operational and compliance policies. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the Company was experiencing delays in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle; (ii) the foregoing issues were negatively impacting the Company’s services business and operations; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times. On July 5, 2017, Diebold disclosed that the Company expected a wider net loss than indicated in its prior guidance for fiscal 2017, from a range of $50 to $75 million to a range of $110 to $125 million net loss.

The Company attributed the lowered expectations to a delay in systems rollouts as well as a longer customer decision-making process and order-to-revenue conversion cycle. 6. Following this news, Diebold’s stock price fell $6.40 per share, or nearly 23%, to close at …

Full story available on Benzinga.com

The post Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Diebold Nixdorf, Intelligent Systems, Helius Medical, and Verb Technology and Encourages Investors to Contact the Firm appeared first on Wolfe’s Blog.

No Image

UPDATE – ChinaCache Announces Changes to the Composition of the Company’s Board of Directors

August 17, 2019 Globe Newswire 0

BEIJING, Aug. 17, 2019 (GLOBE NEWSWIRE) — ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (Nasdaq GS: CCIH), a leading total solutions provider of Internet content and application delivery services in China, today announced changes to the composition of the Company’s Board of Directors (“the Board”).

Ms. Jean Xiaohong Kong and Mr. Yunjie Liu resigned from the management team and the Board on August 15, 2019. Mr. Bin Liu (acting CEO) and Mr. Xiaoqiang Wei (Vice President) were elected to the Board on that same date. In addition, the Board has strengthened its composition with the election of Dong Yu on August 11, 2019, to serve as an independent director of the Company’s Board.

Mr. Dong Yu, a CPA, based in Shanghai, serves as Vice President of Finance, APAC Region for Nexans Cable (China) Co., Limited, a regional subsidiary of Nexans S.A. a global player in the cable and optical fiber industry and second largest global manufacturer of cables. Mr. Yu through his deep experience working …

Full story available on Benzinga.com

The post UPDATE – ChinaCache Announces Changes to the Composition of the Company’s Board of Directors appeared first on Wolfe’s Blog.

No Image

UPDATE – ChinaCache Announces Changes to the Composition of the Company’s Board of Directors

August 17, 2019 Globe Newswire 0

BEIJING, Aug. 17, 2019 (GLOBE NEWSWIRE) — ChinaCache International Holdings Ltd. (“ChinaCache” or the “Company”) (Nasdaq GS: CCIH), a leading total solutions provider of Internet content and application delivery services in China, today announced changes to the composition of the Company’s Board of Directors (“the Board”).

Ms. Jean Xiaohong Kong and Mr. Yunjie Liu resigned from the management team and the Board on August 15, 2019. Mr. Bin Liu (acting CEO) and Mr. Xiaoqiang Wei (Vice President) were elected to the Board on that same date. In addition, the Board has strengthened its composition with the election of Dong Yu on August 11, 2019, to serve as an independent director of the Company’s Board.

Mr. Dong Yu, a CPA, based in Shanghai, serves as Vice President of Finance, APAC Region for Nexans Cable (China) Co., Limited, a regional subsidiary of Nexans S.A. a global player in the cable and optical fiber industry and second largest global manufacturer of cables. Mr. Yu through his deep experience working …

Full story available on Benzinga.com

The post UPDATE – ChinaCache Announces Changes to the Composition of the Company’s Board of Directors appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 26 Deadline in Securities Class Action Lawsuit Against FedEx Corporation – FDX

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of FedEx Corporation (NYSE:FDX) from September 19, 2017 through December 18, 2018, inclusive (t…

The post Zhang Investor Law Reminds Investors of August 26 Deadline in Securities Class Action Lawsuit Against FedEx Corporation – FDX appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 20 Deadline in Securities Class Action Lawsuit Against Anheuser-Busch InBev SA/NV – BUD

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Anheuser-Busch InBev SA/NV (NYSE:BUD) from March 1, 2018 through October 24, 2018, inclusive…

The post Zhang Investor Law Reminds Investors of August 20 Deadline in Securities Class Action Lawsuit Against Anheuser-Busch InBev SA/NV – BUD appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 26 Deadline in Securities Class Action Lawsuit Against Sunlands Technology Group – STG

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Sunlands Technology Group (NYSE:STG) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with Sunlands’s March 2018 initial public stock offering (the “IPO” or the “Offering”). The lawsuit seeks to recover damages for Sunlands investors under the federal securities laws.

If you wish to serve as lead plaintiff, you must move the Court no later than August 26, 2019. A lead plaintiff is a representative party …

Full story available on Benzinga.com

The post Zhang Investor Law Reminds Investors of August 26 Deadline in Securities Class Action Lawsuit Against Sunlands Technology Group – STG appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 20 Deadline in Securities Class Action Lawsuit Against Eros International PLC– EROS

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Eros International PLC (NYSE:EROS) from July 28, 2017 through June 5, 2019, inclusive (the “…

The post Zhang Investor Law Reminds Investors of August 20 Deadline in Securities Class Action Lawsuit Against Eros International PLC– EROS appeared first on Wolfe’s Blog.

No Image

Zhang Investor Law Reminds Investors of August 19 Deadline in Securities Class Action Lawsuit Pivotal Software, Inc. – PVTL

August 16, 2019 Globe Newswire 0

NEW YORK, Aug. 16, 2019 (GLOBE NEWSWIRE) — Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Pivotal Software, Inc. (NYSE:PVTL): (1) pursuant and/or traceable to the registration statement and prospectus (the “Registration Statement”) issued in connection with Pivotal’s April 2018 initial public offering (the “IPO”); and/or (2) between April 24, 2018 and June 4, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Pivotal investors under the federal securities laws.

To join the Pivotal class action, go to http://zhanginvestorlaw.com/join-action-form/?slug=pivotal-software-inc&id=1914 or call Sophie …

Full story available on Benzinga.com

The post Zhang Investor Law Reminds Investors of August 19 Deadline in Securities Class Action Lawsuit Pivotal Software, Inc. – PVTL appeared first on Wolfe’s Blog.

No Image

Psoriasis Treatment Market to Exhibit 8.2% CAGR, Rising Prescription Volume for Interleukin Inhibitors Segment to Boost Market: Fortune Business Insights

August 16, 2019 Globe Newswire 0

Pune, Aug. 16, 2019 (GLOBE NEWSWIRE) — The increasing prevalence of psoriasis around the world is boosting the global Psoriasis Treatment Market, says Fortune Business Insights in their recent report. The report is titled Psoriasis Treatment Market: Global Market Analysis, Insights, and Forecasts, 2018 – 2025.” According to the report, the market will reach US$ 37,634.2 Mn by 2026 from US$ 18,378.0 Mn in 2018, exhibiting a CAGR of 8.2% between 2018 and 2026.

According to the report prepared by Fortune Business Insights, the TNF inhibitors segment emerged dominant among drug classes. In 2018, the TNF inhibitor segment held 46.3% share in the market. However, in the coming years, the market may witness higher demand for biosimilar version leading to the decline in the price of TNF inhibitors. This, accompanied by the increasing prescription volume for interleukin inhibitors segment may help the interleukin inhibitors to emerge as the dominant segment in the coming years.


Browse Complete Report Details with Table of Content and Figures:

https://www.fortunebusinessinsights.com/industry-reports/psoriasis-treatment-market-100600


Rising Prevalence of Plaque Psoriasis to Increase Demand for Treatment, Boosting Market

One of the major factor boosting the global Psoriasis Treatment Market is the increasing prevalence of the disease itself. The World Health Organization states that the prevalence of psoriasis is estimated to vary between 0.09% to 11.0% across all nations. This ultimately means that psoriasis is a serious problem. Psoriasis can occur to anyone irrespective of age but is usually reported to occur to aged people between 50 to 70 years. The rising geriatric population and their vulnerability towards diseases such as psoriatic arthritis are factor propelling growth of the market. These, coupled with the rising prevalence of plaque psoriasis, are likely to create growth opportunities for the market in the forecast period.

The rising availability of biologic and biosimilar products is helping the market for psoriasis grow rapidly. Increase in prescription volume of the biologic products and favorable reimbursement policies by governments are also helping the market grow and continue doing so in the forecast duration as well.

Full story available on Benzinga.com

The post Psoriasis Treatment Market to Exhibit 8.2% CAGR, Rising Prescription Volume for Interleukin Inhibitors Segment to Boost Market: Fortune Business Insights appeared first on Wolfe’s Blog.

No Image

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

August 16, 2019 Globe Newswire 0

MONT-SAINT-GUIBERT, Belgium, Aug. 16, 2019 (GLOBE NEWSWIRE) — Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that the Company will report first half 2019 financial results and business highlights on the evening of Thursday, August 22, 2019.

Following the press release, Celyad management will host a conference call on Friday, August 23 at 2pm CEDT / 8am EDT to discuss first half 2019 results and provide an update on the Company’s recent progress and upcoming milestones.

Participants may access the conference call by dialing any of the following numbers:

  Belgium, Brussels +32 (0) 24 01 70 35  
  France, Paris +33 (0)1 76 72 89 28   
  United States: +1 917 720 0181  
  International: +44 (0) 2071 928501  
  Conference ID: 3547725  

To access the subsequent archived recording, visit the “Events & Webcasts” section of the Celyad website.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal …

Full story available on Benzinga.com

The post Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call appeared first on Wolfe’s Blog.

No Image

Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call

August 16, 2019 Globe Newswire 0

MONT-SAINT-GUIBERT, Belgium, Aug. 16, 2019 (GLOBE NEWSWIRE) — Celyad ((Euronext Brussels and Paris, NASDAQ:CYAD), a clinical-stage biopharmaceutical company focused on the development of CAR-T cell-based therapies, today announced that the Company will report first half 2019 financial results and business highlights on the evening of Thursday, August 22, 2019.

Following the press release, Celyad management will host a conference call on Friday, August 23 at 2pm CEDT / 8am EDT to discuss first half 2019 results and provide an update on the Company’s recent progress and upcoming milestones.

Participants may access the conference call by dialing any of the following numbers:

  Belgium, Brussels +32 (0) 24 01 70 35  
  France, Paris +33 (0)1 76 72 89 28   
  United States: +1 917 720 0181  
  International: +44 (0) 2071 928501  
  Conference ID: 3547725  

To access the subsequent archived recording, visit the “Events & Webcasts” section of the Celyad website.

About Celyad

Celyad is a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based product candidates and utilizes its expertise in cell engineering to target cancer. Celyad’s CAR-T cell platform has the potential to treat a broad range of solid and hematologic tumors. The company’s lead clinical candidate, CYAD-01, an autologous NKG2D-based CAR-T therapy, is currently being evaluated in several Phase 1 clinical trials to assess safety and clinical activity for the treatment of hematological malignancies, such as acute myeloid leukemia, and solid cancers, such as metastatic colorectal cancer. Celyad is also developing CYAD-101, an investigational, non-gene edited, allogeneic (donor derived) NKG2D-based CAR-T therapy, which is currently being evaluated in a Phase 1 trial for the treatment of patients with metastatic colorectal …

Full story available on Benzinga.com

The post Celyad to Provide First Half 2019 Financial Results & Business Highlights and Host a Conference Call appeared first on Wolfe’s Blog.

No Image

Navios Maritime Acquisition Corporation Announces the Date for the Release Second Quarter 2019 Results, Conference Call and Webcast

August 14, 2019 Globe Newswire 0

MONACO, Aug. 14, 2019 (GLOBE NEWSWIRE) — Navios Maritime Acquisition Corporation (“Navios Acquisition”) (NYSE:NNA) announced today that it will host a conference call on Wednesday, August 21, 2019 at 8:30 am ET, at which time Navios Acquisitions’ senior management will provide highlights and commentary on earnings results for the second quarter and six months ended June 30, 2019.

The Company will announce earnings results for the second quarter and six months ended June 30, 2019, prior to the conference call.

A supplemental slide …

Full story available on Benzinga.com

The post Navios Maritime Acquisition Corporation Announces the Date for the Release Second Quarter 2019 Results, Conference Call and Webcast appeared first on Wolfe’s Blog.

No Image

Matrix Service Company Sets Date to Discuss Results for the Fourth Quarter and Fiscal Year Ended June 30, 2019

August 14, 2019 Globe Newswire 0

TULSA, Okla., Aug. 14, 2019 (GLOBE NEWSWIRE) — Matrix Service Company (NASDAQ:MTRX) will announce results for the Fourth quarter and Fiscal Year Ended June 30, 2019, and provide guidance for Fiscal 2020 on Wednesday, August 28, 2019 after the market closes.  The release will be followed by a conference call on Thursday, August 29, 2019 at 10:30 a.m. Eastern time /09:30 a.m. Central time.

Earnings Conference Call instructions

Matrix Service Company will host a conference call with John R. Hewitt, President and CEO and Kevin S. Cavanah, Vice President and CFO at 10:30 a.m. Eastern Time / 09:30 a.m. Central Time on August 29, 2019.  The call will be simultaneously broadcast live over the Internet, which can be accessed at the Company’s website at www.matrixservicecompany.com on the Investors Relations page under Events & Presentations.  Please allow extra time prior to the call to visit the site and download the streaming media software required to listen to the Internet broadcast.  The conference …

Full story available on Benzinga.com

The post Matrix Service Company Sets Date to Discuss Results for the Fourth Quarter and Fiscal Year Ended June 30, 2019 appeared first on Wolfe’s Blog.

No Image

Sportsman’s Warehouse Holdings, Inc. Announces Second Quarter Fiscal 2019 Earnings Conference Call

August 14, 2019 Globe Newswire 0

MIDVALE, Utah, Aug. 14, 2019 (GLOBE NEWSWIRE) — Sportsman’s Warehouse Holdings, Inc. (“Sportsman’s” or the “Company”) (NASDAQ:SPWH) today announced that it will hold its quarterly conference call to discuss second quarter fiscal 2019 financial results on Wednesday, August 28, 2019 at 4:30 p.m. Eastern Time.

The conference call will be …

Full story available on Benzinga.com

The post Sportsman’s Warehouse Holdings, Inc. Announces Second Quarter Fiscal 2019 Earnings Conference Call appeared first on Wolfe’s Blog.

No Image

Chicken Soup for the Soul Entertainment Reports Record Q2 2019 Revenue of $12.2 Million

August 14, 2019 Globe Newswire 0

     Contribution of Crackle Plus for Approximately Half of the Quarter Drives Record Revenue, Increases in Ads Served, and Accelerating Advertising Rates

Pro Forma 2018 Annual Net Revenue of $92.6 Million for Combined Entity

COS COB, Conn., Aug. 14, 2019 (GLOBE NEWSWIRE) — Chicken Soup for the Soul Entertainment, Inc. (CSS Entertainment) (NASDAQ:CSSE), a growing media company building online video-on-demand (VOD) networks that provide video content for all screens, today announced its financial results for the second quarter ended June 30, 2019.

Second Quarter 2019 and Recent Business Highlights
(Results reflect Crackle Plus joint venture closed on May 14, 2019)

  • Total revenue of $12.2 million
  • Net loss of $5.9 million; $5.1 million before preferred dividends
  • Adjusted EBITDA of $1.3 million
  • Crackle Plus streaming video joint venture launched
  • Release of The Man Who Killed Don Quixote, a much anticipated film directed by Terry Gilliam
  • Began production on Season 2 of Chicken Soup for the Soul’s Animal Tales

Total revenue for the quarter ended June 30, 2019 was $12.2 million compared to $3.1 million in the year-ago period. The year-over-year increase reflects 45 days of Crackle contribution.

  • Online networks, which includes Crackle, Popcornflix and Pivotshare, generated $10 million in revenue
  • Television and film distribution generated $2.0 million in revenue
  • Television and short-form video production generated $0.2 million in revenue

“In the second quarter total revenue was a record $12.2 million, reflecting only 45 days of our ownership of Crackle. Our increased scale is driving advertiser interest,” said William J. Rouhana Jr., chairman and chief executive officer of CSS Entertainment. “Our ads served on our owned-and-operated networks increased to 681 million in the second quarter, up from 33 million in the year ago quarter, validating the consolidation strategy. Crackle’s eCPM rate is 27% higher than Popcornflix’s and we expect to increase our ad rates across all of our online networks over time as we close the gap between Popcornflix and Crackle.  These results underscore our excitement for this joint venture.”
             
Gross profit for the quarter ended June 30, 2019 was $3.6 million, or 30% of total revenue, compared to $1.2 million, or 39% of total revenue for the year-ago period. The reduction in the percentage of gross profit was a result of an increase in online networks revenue which has a lower gross profit percentage.  

Operating loss for the quarter ended June 30, 2019 was $3.0 million compared to an operating loss of $1.6 million for the year-ago period. The quarterly operating loss reflects certain non-cash or one-time expenses including $0.7 million in non-cash amortization, $1.2 million of transitional expenses related to the Crackle Plus joint venture, and $1.6 million in film library amortization. If such expenses were excluded from SG&A or cost of revenue, the Company would have reported quarterly operating income of $0.5 million.  

Net loss was $5.9 million, or $0.49 per share, compared to a net loss of $1.7 million, or $0.14 per share in the prior-year second quarter. Excluding preferred dividends, the net loss in the second quarter of 2019 would have been $5.1 million, or approximately $0.42 per share, compared to a net loss of $1.7 million, or $0.14 per share last year.

Adjusted EBITDA for the quarter ended June 30, 2019 was $1.3 million compared to $0.2 million in the same period last year.

As of June 30, 2019, the company had $5.2 million of cash and cash equivalents compared to $7.2 million as of December 31, 2018, and outstanding debt of $7.1 million as of June 30, 2019 compared to $7.6 million as of December 31, 2018.

Crackle Plus Pro Forma Financial Information

CSS Entertainment completed the joint venture launching Crackle Plus on May 14, 2019 (Closing Date). Under generally accepted accounting principles (GAAP), Crackle’s financial results are only included in the combined company’s reported financial results from the Closing Date forward and are not reflected in the combined company’s reported financial results for any periods prior to the Closing Date.

In this release, to supplement and aid in an understanding of the combined company’s reported financial results, CSS Entertainment is also providing certain GAAP-based and non-GAAP pro forma financial information of the combined company that includes Crackle’s financial results for the relevant periods prior to the Closing Date, as if the acquisition occurred on January 1, 2018. See “Use of Non-GAAP Measures and Supplementary Information” below and the accompanying financial schedules for more information, including descriptions of any such pro forma measures that may be non-GAAP measures and reconciliations of those non-GAAP measures to their most directly comparable GAAP measures. Please refer to the Company’s recently filed Amendment No. 1 to the Current Report on Form 8-K/A filed with the Securities and Exchange Commission on July 30, 2019 for further details on pro forma results disclosed herein.

“This was an incredibly productive and busy quarter as we completed the joint venture creating Crackle Plus,” said Mr. Rouhana. “We are now one of the largest ad-supported networks in the industry and have solidified our position as a leader in the high-growth, advertising-supported VOD (AVOD) business. Before we entered into the joint venture agreement, we had identified a number of synergistic opportunities and cost reduction targets, which enabled a smooth integration. As a result, and as detailed in the recently filed Form 8-K/A, we have streamlined the organization, eliminating approximately $65.3 million in total annualized costs on an estimated pro forma combined 2018 net revenue of $92.6 million.”

“The four key areas we identified to reduce costs and improve margins were in technology, marketing, content and SG&A,” continued Mr. Rouhana. “Estimated pro forma reductions of $29.6 million in Cost of Goods Sold (COGS) were primarily due to consolidating technology costs onto a shared platform and replacing fixed fee content agreements with revenue sharing agreements. On the SG&A front, duplicative roles in the operations teams were eliminated, and we streamlined allocated corporate overhead expenses. Our marketing spend was also significantly reduced by excluding certain marketing agreements from transferred assets and using our owned-and-operated networks and brand related social media. These measures resulted in estimated pro forma S&GA annual cost reductions of $35.6 million and $25.3 million in annual pro forma adjusted EBITDA.”

“Now that Crackle is fully integrated, we intend to focus on further acquisitions of online networks, adding to our ad partner network, and growing our film distribution activity,” said Mr. Rouhana. “We also plan to grow our television and short-form video production platform while reducing the risk capital allocated to these projects. We anticipate our proprietary content production contributing more significantly to revenue next year, demonstrating the potential synergies in our business.”

For a discussion of the financial measures presented herein which are not calculated or presented in accordance with U.S. generally accepted accounting principles (“GAAP”), see “Note Regarding Use of Non-GAAP Financial Measures” below and the schedules to this press release for additional information and reconciliations of non-GAAP financial measures.

The company presents non-GAAP measures such as Adjusted EBITDA and Pro Forma Adjusted EBITDA to assist in an analysis of its business. These non-GAAP measures should not be considered an alternative to GAAP measures as an indicator of the Company’s operating performance.

Conference Call Information

  • Date, Time: Wednesday, August 14, 2019, 4:30 p.m. ET.
  • Toll-free: (833) 832-5128
  • International: (484) 747-6583
  • Conference ID: 2279818
  • A live webcast is available at http://ir.cssentertainment.com/ under the “News & Events” tab

Conference Call Replay Information

  • Toll-free: (855) 859-2056
  • International: (404) 537-3406
  • Reference ID: 2279818

ABOUT CHICKEN SOUP FOR THE SOUL ENTERTAINMENT

Chicken Soup for the Soul Entertainment, Inc. is a growing media company building and acquiring streaming VOD networks that provide content for all screens. CSS Entertainment has a majority stake in Crackle Plus, a joint venture with Sony Pictures Television, which owns and operates a variety of ad-supported and subscription-based VOD networks including Crackle, Popcornflix, Popcornflix Kids, Truli, Pivotshare, Españolflix and FrightPix. CSS Entertainment also acquires and distributes video content through its Screen Media subsidiary and produces long- and short-form content through its Chicken Soup for the Soul Originals division and through APlus.com. Chicken Soup for the Soul Entertainment is a subsidiary of Chicken Soup for the Soul, LLC, which publishes the famous book series and produces super-premium pet food under the Chicken Soup for the Soul brand name.

Note Regarding Use of Non-GAAP Financial Measures

The company’s consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“GAAP”). It uses a non-GAAP financial measure to evaluate its results of operations and as a supplemental indicator of operating performance. The non-GAAP financial measure that is used is Adjusted EBITDA. Adjusted EBITDA (as defined below) is considered a non-GAAP financial measure as defined by Regulation G promulgated by the SEC under the Securities Act of 1933, as amended. Management believes this non-GAAP financial measure enhances the understanding of the company’s historical and current financial results and enables the board of directors and management to analyze and evaluate financial and strategic planning decisions that will directly affect operating decisions and investments. The presentation of Adjusted EBITDA should not be construed as an inference that future results will be unaffected by unusual or non-recurring items or by non-cash items. This non-GAAP financial measure should be considered in addition to, rather than as a substitute for, the company’s actual operating results included in its condensed consolidated financial statements.

“Adjusted EBITDA” means earnings before interest, taxes, depreciation, amortization and non-cash share-based compensation expense, and also includes the gain on bargain purchase of subsidiary and adjustments for other identified charges such as costs incurred to form the company and to prepare for the offering of its Class A common stock to the public, prior to its IPO. Identified charges also include the cost of maintaining a board of directors prior to being a publicly traded company. As the IPO has been completed, director fees will be deducted from Adjusted EBITDA going forward. Adjusted EBITDA is not an earnings measure recognized by GAAP and does not have a standardized meaning prescribed by GAAP; accordingly, Adjusted EBITDA may not be comparable to similar measures presented by other companies. Management believes Adjusted EBITDA to be a meaningful indicator of the company’s performance that provides useful information to investors regarding its financial condition and results of operations. The most comparable GAAP measure is operating income.

A reconciliation of net loss to Adjusted EBITDA is provided in the company’s Quarterly Report on Form 10-Q for the three months ended June 30, 2019 under “Management’s Discussion and Analysis of Financial Condition and Results of Operations – Reconciliation of Unaudited Historical Results to Adjusted EBITDA.”

FORWARD-LOOKING STATEMENTS

This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks (including those set forth in the Annual Report on Form 10-K, filed with the Securities and Exchange Commission on April 1, 2019, as amended April 30, 2019 and June 4, 2019) and uncertainties which could cause actual results to differ from the forward-looking statements. The company expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Investors should realize that if our underlying assumptions for the projections contained herein prove inaccurate or that known or unknown risks or uncertainties materialize, actual results could vary materially from our expectations and projections.

INVESTOR RELATIONS
James Carbonara
Hayden IR
james@haydenir.com
(646) 755-7412

MEDIA CONTACT
Kate Barrette
RooneyPartners LLC
kbarrette@rooneyco.com
(212) 223-0561 

Tables Follow

   
  Chicken Soup for the Soul Entertainment, Inc.
   Pro Forma Condensed Consolidated Combined Statement of Operations
  For the Year Ended December 31, 2018 
  (audited) 
   
   
    CSS       Pro Forma   Pro Forma
      Entertainment   Crackle U.S. (1)   Adjustments   Combined
            Revenue, net     26,859,519       65,784,308           92,643,827  
  Cost of revenue      12,345,590       65,558,710       (29,629,305 )     48,274,995  
            Gross profit     14,513,929       225,598       29,629,305       44,368,832  
  Operating expenses:                
    Selling, general and administrative      10,745,235       44,357,633       (35,943,445 )     19,159,423  
    Management and license fees      2,666,907       –        6,578,431       9,245,338  
            Total operating expenses     13,412,142       44,357,633       (29,365,014 )     28,404,761  
  Operating (loss) / income before Amortization     1,101,787       (44,132,035 )     58,994,320       15,964,071  
    Amortization      326,988       –        4,194,952       4,521,940  
  Operating (loss) / income     774,799       (44,132,035 )     54,799,367       11,442,131  
  Interest income      39,058       –            39,058  
  Interest expense      (388,036 )     –        –        (388,036 )
  Acquisition-related costs     (396,793 )     –        –        (396,793 )
  Goodwill impairment expense         (8,800,000 )     –        (8,800,000 )
  Income / (loss) before income taxes and preferred dividends      29,028       (52,932,035 )     54,799,367       1,896,360  
  Provision for (benefit from) income taxes     874,000       –        (363,310 )     510,690  
  Net (loss) / income before noncontrolling interests and preferred dividends     (844,972 )     (52,932,035 )     55,162,678       1,385,671  
  Net (Loss) / income attributable to noncontrolling interests             38,100       38,100  
  Net (loss) / income attributable to Chicken Soup for the Soul Entertainment, Inc.     (844,972 )     (52,932,035 )     55,124,577       1,347,570  
  Preferred dividends      1,112,910       –        –        1,112,910  
  Net (loss) / income available to common Stockholders $   (1,957,882 )     (52,932,035 )     55,124,577       234,660  
  Net (loss) / income per common share:                
  Basic and diluted  $   (0.16 )             0.02  
  Weighted average number of common shares outstanding:                
  Basic and diluted      11,944,528    

Full story available on Benzinga.com

The post Chicken Soup for the Soul Entertainment Reports Record Q2 2019 Revenue of $12.2 Million appeared first on Wolfe’s Blog.

No Image

LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2019

August 14, 2019 Globe Newswire 0

Reports Highest Annual Revenue in Company History

Fiscal 2019 Revenue Increased 11% and Adjusted EBITDA Increased 22%

Exceeds High End of Fiscal 2019 Adjusted EPS Guidance

SALT LAKE CITY, Aug. 14, 2019 (GLOBE NEWSWIRE) — LifeVantage Corporation (NASDAQ:LFVN) today reported financial results for its fourth quarter and full fiscal year ended June 30, 2019.

Fourth Quarter Fiscal 2019 Highlights:

  • Revenue increased 4.0% to $56.2 million year over year;
  • Revenue in the Americas decreased 2.9% year over year, while revenue in Asia/Pacific & Europe increased 24.4% year over year;
  • Active members increased 3.4% to 185,000, including 4.8% growth of independent distributors and a 2.6% increase in active customers, each on a year over year basis;
  • Adjusted EBITDA increased 48.6% to $7.7 million year over year;
  • Earnings per diluted share were $0.26, compared to $0.21 in the prior year period; and
  • Adjusted earnings per diluted share were $0.26, compared to $0.20 in the prior year period.

* All year over year growth rates compare the fourth quarter of fiscal 2019 to the fourth quarter of fiscal 2018.

Fiscal Year 2019 Highlights:

  • Revenue increased 11.2% to $226.0 million;
  • Revenue in the Americas increased 7.7% and revenue in Asia/Pacific & Europe increased 21.6%;
  • Adjusted EBITDA increased 22.4% to $18.2 million;
  • Earnings per diluted share were $0.50, compared to $0.41 in fiscal 2018;
  • Adjusted earnings per diluted share were $0.59, compared to $0.51 in fiscal 2018; and
  • Repurchased 389,000, or $4.7 million, of common shares, and paid down $4.0 million of long-term debt, reflecting strong cash flow from operations of $17.8 million.

*All growth rates compare fiscal 2019 to fiscal 2018.

“We are proud to report a strong finish to fiscal 2019, generating the highest annual revenue in the Company’s history while exceeding our fiscal 2019 adjusted EPS guidance,” stated LifeVantage President and Chief Executive Officer, Darren Jensen. “We continue to see positive trends in our active member counts, reflecting successful execution of each of our 2019 strategic initiatives. We have also expanded our geographic footprint and enhanced our innovative product offering. Looking to fiscal 2020, we remain focused on the key drivers of our continued growth, while embracing new initiatives with the intent to expand these drivers and capitalize on the ever growing global consumer interest in improving health and enhancing lifestyles. Our key initiatives for 2020 include growing our biohacking subscriptions, attracting and creating influencers to expand reach, simplifying the business building opportunity at LifeVantage and building a solid foundation for future growth. I am confident that the future remains bright for LifeVantage and I look forward to executing on our plans for fiscal 2020 and beyond.”

Fourth Quarter Fiscal 2019 Results

For the fourth fiscal quarter ended June 30, 2019, the Company reported revenue of $56.2 million, an increase of 4.0% as compared to $54.0 million in the fourth quarter of fiscal 2018. Revenue in the Americas for the fourth quarter decreased 2.9% compared to the fourth quarter of fiscal 2018 and revenue in the Asia/Pacific & Europe region increased 24.4% compared to the fourth quarter of fiscal 2018. Revenue for the fourth quarter of fiscal 2019 was negatively impacted $0.4 million, or 0.7%, by foreign currency fluctuations associated with revenue generated in international markets when compared to the fourth quarter of fiscal 2018.

Gross profit for the fourth quarter of fiscal 2019 was $46.5 million, or 82.7% of revenue, compared to $46.0 million, or 85.1% of revenue, for the same period in fiscal 2018. The decrease in gross margin was largely driven by a benefit of $0.9 million in the fourth quarter of fiscal 2018 due to a change in accrued import estimates. Normalized for this change, adjusted non-GAAP gross profit was comparable to the prior year period.

Commissions and incentives expense for the fourth quarter of fiscal 2019 was $25.5 million, or 45.3% of revenue, compared to $27.1 million, or 50.1% of revenue, for the same period in fiscal 2018. The year over year decrease reflects the timing of accruals for incentive and promotional programs.

Selling, general and administrative expense (SG&A) for the fourth quarter of fiscal 2019 was $15.3 million, or 27.3% of revenue, compared to $14.6 million, or 27.0% of revenue, for the same period in fiscal 2018. Adjusted for other nonrecurring legal and accounting expenses of $0.1 million and class-action lawsuit expenses of $37,000, adjusted non-GAAP SG&A expenses for the fourth quarter of fiscal 2019 were $15.2 million or 27.1% of revenue. Adjusted for class-action lawsuit expenses of $0.3 million, executive severance, recruiting and transition expenses of $0.3 million and benefits from insurance reimbursements of $0.4 million, adjusted non-GAAP SG&A expenses for the fourth quarter of fiscal 2018 were $14.4 million or 26.6% of revenue. The modest year over year increase in non-GAAP SG&A was primarily due to increased expenses associated with stock and other employee incentive compensation programs, which increased as a result of improved revenue performance and increases in the Company’s share price as compared to the prior year period.

Operating income for the fourth quarter of fiscal 2019 was $5.7 million, compared to $4.3 million for the fourth quarter of fiscal 2018. Accounting for the non-GAAP adjustments noted previously, adjusted non-GAAP operating income for the fourth quarter of fiscal 2019 was $5.8 million, compared to $3.7 million for the fourth quarter of fiscal 2018.

Adjusted EBITDA increased 48.6% to $7.7 million for the fourth quarter of fiscal 2019, compared to $5.2 million for the comparable period in fiscal 2018.

Net income for the fourth quarter of fiscal 2019 was $3.9 million, or $0.26 per diluted share. This compares to net income for the fourth quarter of fiscal 2018 of $3.0 million, or $0.21 per diluted share. Accounting for the non-GAAP adjustments noted previously, and tax impacts of these adjustments of $27,000, adjusted non-GAAP net income for the fourth quarter of fiscal 2019 increased 41.6% to $4.0 million, or $0.26 per diluted share. Accounting for the non-GAAP adjustments noted previously, and tax impacts of these adjustments of $0.2 million as well as tax expense of $0.3 million associated with the revaluation of deferred tax assets associated with the 2017 tax reform, adjusted non-GAAP net income for the fourth quarter of fiscal 2018 was $2.8 million, or $0.20 per diluted share.

Fiscal 2019 Full Year Results

For the fiscal year ended June 30, 2019, the Company reported net revenue of $226.0 million, an increase of 11.2% compared to $203.2 million for fiscal 2018. In fiscal 2019, revenue in the Americas increased 7.7% and revenue in Asia/Pacific & Europe increased 21.6%. Revenue for fiscal 2019 was negatively impacted $1.6 million, or 0.8%, by foreign currency fluctuations associated with revenue generated in international markets.

Gross profit during fiscal 2019 was $188.0 million, or 83.2% of revenue, compared to $168.4 million, or 82.9% of revenue, for fiscal 2018. The increase in gross margin was primarily due to benefits of a price increase during the second half of fiscal 2018, decreased inventory obsolescence and handling costs, partially offset by changes to our geographic and product sales mix related to the revenue growth and product expansion outside of the United States. Fiscal 2018 gross profit benefited by $0.9 million due to a change in accrued import estimates. Adjusted non-GAAP gross profit for fiscal 2018 was $167.5 million, or 82.4%.

Commissions and incentives expense for fiscal 2019 was $108.6 million, or 48.1% of revenue, compared to $98.2 million, or 48.3% of revenue, for fiscal 2018. Commissions and incentives expense, as a percentage of revenue, remained consistent on a comparative basis.

SG&A for fiscal 2019 was $69.6 million, or 30.8% of revenue, compared to $59.8 million, or 29.4% of revenue, for fiscal 2018. Adjusted for class-action lawsuit expenses of $0.6 million and nonrecurring legal and accounting expenses of $0.5 million, partially offset by a benefit associated with executive severance of $0.1 million, adjusted non-GAAP SG&A for fiscal 2019 was $68.5 million, or 30.3% of revenue. Adjusted for class-action lawsuit expenses of $0.7 million, executive severance, recruiting and transition expenses of $0.6 million, nonrecurring legal and accounting expenses of $0.1 million and benefits from insurance reimbursements received of $0.4 million, adjusted non-GAAP SG&A for fiscal 2018 was $59.0 million, or 29.0% of revenue. The $9.6 million year over year increase in non-GAAP SG&A was primarily due to increased expenses associated with stock and other employee incentive compensation programs, which increased as a result of improved revenue performance and increases in the Company’s share price as compared to the prior year period, costs associated with higher staffing levels added in late fiscal 2018, and due to increased expenses associated with Global Convention, Japan Convention and a Japan Elite Academy.

Operating income during fiscal 2019 was $9.8 million, compared to $10.3 million for fiscal 2018. Accounting for non-GAAP adjustments noted previously, adjusted non-GAAP operating income for fiscal 2019 was $10.8 million compared to $10.3 million for fiscal 2018.

Adjusted EBITDA increased 22.4% to $18.2 million for fiscal 2019, compared to $14.9 million for fiscal 2018.

Net income during fiscal 2019 was $7.4 million, or $0.50 per diluted share, compared to $5.8 million, or $0.41 per diluted share for fiscal 2018. Accounting for the non-GAAP adjustments noted previously, and tax benefits of these adjustments of $0.4 million, adjusted non-GAAP net income for fiscal 2019 increased 23.6% to $8.9 million, or $0.59 per diluted share. Accounting for the non-GAAP adjustments noted previously, and tax impacts of these adjustments of $42,000, as well as tax expense of $1.5 million associated with the revaluation of deferred tax assets associated with the 2017 tax reform, adjusted non-GAAP net income for fiscal 2018 was $7.2 million, or $0.51 per diluted share.

Balance Sheet & Liquidity

The Company generated $17.8 million of cash from operations during fiscal 2019 compared to $13.3 million in the comparable period of fiscal 2018. The Company’s cash and cash equivalents at June 30, 2019 were $18.8 million, compared to $16.7 million at June 30, 2018. Total debt at June 30, 2019 was $1.5 million, compared to $5.4 million at June 30, 2018. During fiscal 2019, the Company repurchased $4.7 million of common shares under its share repurchase authorization.

Fiscal Year 2020 Guidance

The Company expects to generate revenue in the range of $235 million to $245 million in fiscal year 2020 and adjusted EBITDA of $20 million to $22 million, with adjusted earnings per share in the range of $0.62 to $0.71, which assumes a full year tax rate in the range of 19% to 22%. The Company’s adjusted non-GAAP EBITDA and adjusted non-GAAP earnings per diluted share guidance excludes any non-operating or non-recurring expenses that may materialize during fiscal 2020. The Company is not providing GAAP earnings per diluted share guidance for fiscal 2020 due to the potential occurrence of one or more non-operating, one-time expenses, which the Company does not believe it can reliably predict.

Conference Call Information

The Company will hold an investor conference call today at 2:30 p.m. MDT (4:30 p.m. EDT). Investors interested in participating in the live call can dial (800) 289-0438 from the U.S. International callers can dial (323) 794-2423. A telephone replay will be available approximately two hours after the call concludes and will be available through Wednesday, August 21, 2019, by dialing (844) 512-2921 from the U.S. and entering confirmation code 4077209, or (412) 317-6671 from international locations, and entering confirmation code 4077209.

There will also be a simultaneous, live webcast available on the Investor Relations section of the Company’s web site at https://lifevantage.gcs-web.com/events-and-presentations. The webcast will be archived for approximately 30 days.

About LifeVantage Corporation

LifeVantage Corporation (NASDAQ:LFVN) is a pioneer in Nutrigenomics – a new science dedicated to biohacking the human aging code. The Company engages in the identification, research, development and distribution of advanced nutrigenomic dietary supplements and skin and hair care products, including its Protandim® product line, LifeVantage® Omega+ and ProBio dietary supplements, the TrueScience® line of Nrf2-infused skin and hair care products, Petandim™ for Dogs, Axio® Smart Energy Drink mixes, and the PhysIQ™ Smart Weight Management System. LifeVantage was founded in 2003 and is headquartered in Salt Lake City, Utah. For more information, visit www.lifevantage.com.

Forward Looking Statements

This document contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believe”, “hopes”, “intends”, “estimates”, “expects”, “projects”, “plans”, “anticipates”, “look forward to”, “goal”, “may be”, and variations thereof, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. Examples of forward-looking statements include, but are not limited to, statements we make regarding the benefits of our key initiatives, future growth and expected financial performance. Such forward-looking statements are not guarantees of performance and the Company’s actual results could differ materially from those contained in such statements. These forward-looking statements are based on the Company’s current expectations and beliefs concerning future events affecting the Company and involve known and unknown risks and uncertainties that may cause the Company’s actual results or outcomes to be materially different from those anticipated and discussed herein. These risks and uncertainties include, among others, those discussed in greater detail in the Company’s Annual Report on Form 10-K and the Company’s Quarterly Report on Form 10-Q under the caption “Risk Factors,” and in other documents filed by the Company from time to time with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this document, except as required by …

Full story available on Benzinga.com

The post LifeVantage Announces Financial Results for the Fourth Fiscal Quarter and Full Fiscal Year 2019 appeared first on Wolfe’s Blog.

No Image

Domo Announces Timing of its Second Quarter Fiscal 2020 Results Conference Call

August 14, 2019 Globe Newswire 0

SILICON SLOPES, Utah, Aug. 14, 2019 (GLOBE NEWSWIRE) — Domo (NASDAQ:DOMO), provider of the leading cloud-based operating system for business, today announced that results for its second quarter fiscal 2020 (ended July 31, 2019) will be released on …

The post Domo Announces Timing of its Second Quarter Fiscal 2020 Results Conference Call appeared first on Wolfe’s Blog.

Fed Chief Judge Orders Recast of Trial Judges in Deadlocked SEC Case

August 13, 2019 Globe Newswire 0

CAMDEN, N.J., Aug. 12, 2019 (GLOBE NEWSWIRE) — Last Thursday, upon the federal chief of justice in the New Jersey District ordering a recall and reassignment of two federal judges in a civil lawsuit for securities fraud claims filed by the Securities and  Exchange Commission, trial court proceedings continued after a three-year deadlock and dormant status of the civil suit filed by SEC New York Division (in the New Jersey District of The Third  Circuit), that was initially part of a parallel action with the Department of Justice in New Jersey, who filed criminal charges against lobbyist Cary Peterson for the securities fraud and false certification allegations four days before the SEC filed a civil lawsuit against him and a public shell company he had been in the process of buying, for the same allegations as the attorney general.

SEC V. RVPLUS INC.TEXT ORDER FOR RECUSAL AND REASSIGNMENT OF JUDGES
Copyright Info: New World Order Politics (with podcast host David Delivera)

On or about June 12, 2019, political activist (now political prisoner), Cary Lee Peterson successfully filed and was granted ‘extraordinary  (interlocutory) relief from an emergency cross-attack motion called a prerogative writ, in efforts to jostle the Third Circuit Court of Appeals to enjoin the six-month deadlock status of appeal proceedings for his release while awaiting appeal decision and reversal of his criminal judgment of conviction from the U.S. District Court in Trenton, New Jersey.

In accordance to rules of judicial comity, Peterson’s special (prerogative) writ granted by U.S. Circuit Court Judge Restrepo, theoretically would be extended to related cases in a lower court, which resulted in the federal chief judge in New Jersey to recuse and reassign two judges originally assigned to SEC v. RVPlus, Inc. (civil case) back in 2016.

Hence, the text order by Chief Justice Freda L. Wolfson’s ‘text order reassigning judges’ recasted U.S. District Court Judge William H. Walls and Magistrate Cathy L. Waldorf shortly after Peterson filed the Bernie Sanders Gotcha Evidence, in June,  to compel the court to acknowledge the primary cause of the SEC case and the criminal parallel action launched by [then] U.S. Attorney Paul J. Fishman, who President Donald J. Trump and the U.S. Supreme Court asked to resign, after the  2017 presidential inauguration. Thereafter, Fishman returned to work in the private sector, as a legal partner at Kaye and Scholer law firm, who also employs (private) attorney associate, Ari B. Fontecchio, who Fishman hired as a (543) ‘special’ trial prosecutor in Peterson’s criminal case a month before he was succeeded by (interim) Acting U.S. Attorney William E. Fitzpatrick on January 2017.

Prior to Chief Judge Wolfson’s reassignment order, Peterson filed a legal brief confronting the district court judges’ disability, non-direction, and judicial conduct and discretion in bad faith, that resulted in several uncontested motions docket that were filed by Peterson as far back as the end of last year through the present.

Peterson had reiterated pleadings that the SEC civil complaint had sufficient grounds for dismissal due to lack of jurisdiction or venue, failed or improper service of process, and collateral estoppel- being that the SEC previously entered a stipulation agreement following …

Full story available on Benzinga.com

The post Fed Chief Judge Orders Recast of Trial Judges in Deadlocked SEC Case appeared first on Wolfe’s Blog.

Medical Solutions to Acquire C&A Industries, Inc.

August 12, 2019 Globe Newswire 0

Omaha, Nebraska, Aug. 12, 2019 (GLOBE NEWSWIRE) —

Medical Solutions, one of the nation’s largest healthcare staffing companies, today announced a definitive agreement to acquire C&A Industries, Inc., one of the most respected, family-owned staffing and recruitment firms in the country. Based in Omaha, Neb., C&A Industries is the parent company to a portfolio of workforce solutions firms including Aureus Group®, Aureus Medical Group®, AurStaff®, Celebrity Staff™, and FocusOne Solutions®, along with non-staffing affiliates, AurTravel® and AurHomes®. As part of the transaction, C&A Industries will continue to operate out of its existing headquarters in Omaha. The transaction is subject to customary closing conditions, including regulatory clearance, and is expected to close by the end of the third quarter of 2019. Additional terms of the transaction were not disclosed.

0_medium_MedicalSolutions_LogoCOLOR-v4.png
2_medium_MedicalSolutions_LogoCOLOR-v4.png

Medical Solutions offers a range of dynamic staffing solutions aimed to address hospitals’ specific and ever-changing needs. The company connects more than 2,200 healthcare facilities across the country with highly skilled and qualified healthcare professionals. It also operates as a managed service provider (MSP), helping to streamline and simplify workforce operations by exclusively managing a hospital’s entire contingent labor staffing process.

“We’re thrilled by the opportunity to combine two industry leaders to create the premier U.S. healthcare staffing company based in Omaha,” said Craig Meier, CEO of Medical Solutions. “We are very excited to carry on the legacy and tradition of what C&A Industries has built over the past 50 years. Our businesses share a like-minded foundation and unwavering commitment to creating exceptional experiences for our employees and clients, and we look forward to strengthening this foundation together.”

“C&A Industries represents my life’s work and entrepreneurial vision that began just over 50 years ago. Looking back at our accomplishments and milestones, our steady expansion, and our strength in the most challenging of economic climates, we have led the way and remained at the forefront of our industry,” …

Full story available on Benzinga.com

The post Medical Solutions to Acquire C&A Industries, Inc. appeared first on Wolfe’s Blog.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In 3M Company To Contact The Firm

August 12, 2019 Globe Newswire 0

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in 3M Company (“3M” or the “Company”) (NYSE:MMM) of the September 27, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in 3M stock or options between February 9, 2017 and May 28, 2019 and would like to discuss your legal rights, click here: www.faruqilaw.com/MMMThere is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. 

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn:  Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased 3M securities between February 9, 2017 and May 28, 2019 (the “Class Period”).  The case, Heavy & General Laborers’ Locals 472 & 172 Welfare Fund V. 3M Company, No. 2:19-cv-15982 was filed on July 29, 2019, and has been assigned to Judge Claire C. Cecchi.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by issuing false and misleading statements to conceal the truth …

Full story available on Benzinga.com

The post LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In 3M Company To Contact The Firm appeared first on Wolfe’s Blog.

NETFLIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In Netflix, Inc. To Contact The Firm

August 12, 2019 Globe Newswire 0

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Netflix, Inc. (“Netflix” or the “Company”)(NASDAQ:NFLX).

If you invested in Netflix stock or options and would like to discuss your legal rights, click here:

Full story available on Benzinga.com

The post NETFLIX INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $500,000 Investing In Netflix, Inc. To Contact The Firm appeared first on Wolfe’s Blog.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Reckitt Benckiser Group plc To Contact The Firm

August 12, 2019 Globe Newswire 0

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Reckitt Benckiser Group plc (“Reckitt” or the “Company”)(OTC:RBGLY) of the September 13, 2019 deadline…

The post LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Reckitt Benckiser Group plc To Contact The Firm appeared first on Wolfe’s Blog.

LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ideanomics, Inc. To Contact The Firm

August 12, 2019 Globe Newswire 0

NEW YORK, Aug. 12, 2019 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Ideanomics, Inc. (“Ideanomics” or the “Company”) (NASDAQ:IDEX) of the September 17, 2019 deadline to seek the role of …

The post LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Ideanomics, Inc. To Contact The Firm appeared first on Wolfe’s Blog.

IES HONORS HEALTHE’S SUNTRAC™ ECOSYSTEM IN ITS 2019 PROGRESS REPORT

August 12, 2019 Globe Newswire 0

Cocoa Beach, FL, Aug. 12, 2019 (GLOBE NEWSWIRE) — In its 2019 Progress Report, the Illuminating Engineering Society (IES) recognizes Healthe’s SunTrac™ Ecosystem as a significant advancement of lighting technology.  SunTrac brings the healthy, dynamic spectrum of the sun indoors by automatically adjusting its True Circadian™ spectrum and intensity throughout the day. The wavelengths of light produced use Healthe’s proprietary technology to go beyond color temperature – they target the body’s peak circadian sensitivity and are delivered based on the time of the day to promote a healthy circadian rhythm and sleep/wake cycle. 

0_medium_SuntracEcosystem1500x15001.jpg
The SunTrac™ Ecosystem brings simplicity and convenience to biological lighting. Advanced technology in familiar and convenient form factors combine our popular sleep-enhancing GoodNight® spectrum and our GoodDay® energy-enhancing spectrum, easily replacing traditional lighting with healthy circadian lighting. Now you …

Full story available on Benzinga.com

The post IES HONORS HEALTHE’S SUNTRAC™ ECOSYSTEM IN ITS 2019 PROGRESS REPORT appeared first on Wolfe’s Blog.

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reckitt Benckiser Group plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

August 12, 2019 Globe Newswire 0

LOS ANGELES, Aug. 12, 2019 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Reckitt Benckiser Group plc (“Reckitt” or “the Company”) (OTC: RBGLY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s American Depository Shares (“ADSs”) between July 28, 2014 and April 9, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 13, 2019.          

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law …

Full story available on Benzinga.com

The post INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reckitt Benckiser Group plc and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm appeared first on Wolfe’s Blog.

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intelligent Systems Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

August 12, 2019 Globe Newswire 0

LOS ANGELES, Aug. 12, 2019 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Intelligent Systems Corporation (“Intelligent Systems” or “the Company”) (NYSE: INS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s securities between January 23, 2019 and May 29, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 9, 2019.   

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian …

Full story available on Benzinga.com

The post INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Intelligent Systems Corporation and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm appeared first on Wolfe’s Blog.

Government of Canada invests in cutting-edge tools for universities

August 12, 2019 Globe Newswire 0

EDMONTON, Alberta, Aug. 12, 2019 (GLOBE NEWSWIRE) — Researchers across the country need the best labs and tools to spark discoveries that lead to healthy communities, clean air and water, new job opportunities and a prosperous future. That’s why the Honourable Kirsty Duncan, Minister of Science and Sport, today announced more than $61 million for state-of-the-art research labs and equipment through the Canada Foundation for Innovation’s (CFI) John R. Evans Leaders Fund (JELF). This investment will support 261 projects at 40 universities across Canada.

The Fund helps exceptional university scientists conduct leading-edge research by giving them the tools and equipment they need to become leaders in their field. The University of Alberta is receiving more than $2.2 million for 10 research infrastructure projects that will, among other things, ensure food safety, improve end-of-life care for patients, reclaim mining sites and reduce air pollution.

This investment will also help support Dr. Sandra Davidge, a pioneer in cardiovascular health in women and children at the University of Alberta. She is receiving funding for specialized imaging equipment that will enable her and her team to understand the link between low oxygen flow to an unborn baby and the risk of cardiovascular disease later in life. The team’s work will help create early interventions that will allow these babies to grow into heart-healthy adults. This is just one example of how new investments in research infrastructure trigger innovations that affect the lives of everyday Canadians.  

While in Edmonton, Minister Duncan also signed the Dimensions Charter with the University of Alberta. …

Full story available on Benzinga.com

The post Government of Canada invests in cutting-edge tools for universities appeared first on Wolfe’s Blog.

INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

August 12, 2019 Globe Newswire 0

LOS ANGELES, Aug. 12, 2019 (GLOBE NEWSWIRE) — The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Helius Medical Technologies, Inc. (“Helius” or “the Company”) (NASDAQ: HSDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company’s shares between November 9, 2017 and April 10, 2019, inclusive (the ”Class Period”), are encouraged to contact the firm before September 9, 2019.

If you are a shareholder who suffered a loss, click here to participate.

We also …

Full story available on Benzinga.com

The post INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Helius Medical Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm appeared first on Wolfe’s Blog.

No Image

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Realogy Holdings Corporation – RLGY

August 10, 2019 Globe Newswire 0

NEW YORK, Aug. 10, 2019 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of Realogy Holdings Corporation  (“Realogy” or the “Company”) (NYSE:RLGY).   Such investors are advised to contact Robert S. Willoughby at rswil…

The post SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Realogy Holdings Corporation – RLGY appeared first on Wolfe’s Blog.

No Image

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of 3M Company – MMM

August 10, 2019 Globe Newswire 0

NEW YORK, Aug. 10, 2019 (GLOBE NEWSWIRE) — Pomerantz LLP is investigating claims on behalf of investors of 3M Company (“3M” or the “Company”) (NYSE:MMM). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-4…

The post SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of 3M Company – MMM appeared first on Wolfe’s Blog.